Svedbom A - Search Results

1

Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence.

Dalén J, Svedbom A, Black CM, Lyu R, Ding Q, Sajjan S, Sazonov V, Kachroo S. Dalén J, et al. Among authors: svedbom a. Rheumatol Int. 2016 Jul;36(7):987-95. doi: 10.1007/s00296-016-3423-5. Epub 2016 Jan 16. Rheumatol Int. 2016. PMID: 26780533

2

Treatment patterns with topicals, traditional systemics and biologics in psoriasis - a Swedish database analysis.

Svedbom A, Dalén J, Mamolo C, Cappelleri JC, Petersson IF, Ståhle M. Svedbom A, et al. J Eur Acad Dermatol Venereol. 2015 Feb;29(2):215-223. doi: 10.1111/jdv.12494. Epub 2014 May 12. J Eur Acad Dermatol Venereol. 2015. PMID: 24813476 Review.

3

Increased cause-specific mortality in patients with mild and severe psoriasis: a population-based Swedish register study.

Svedbom A, Dalén J, Mamolo C, Cappelleri JC, Mallbris L, Petersson IF, Ståhle M. Svedbom A, et al. Acta Derm Venereol. 2015 Sep;95(7):809-15. doi: 10.2340/00015555-2095. Acta Derm Venereol. 2015. PMID: 25766866 Free article.

4

Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line.

Svedbom A, Dalén J, Black CM, Kachroo S. Svedbom A, et al. Patient Prefer Adherence. 2017 Jan 16;11:95-106. doi: 10.2147/PPA.S119808. eCollection 2017. Patient Prefer Adherence. 2017. PMID: 28144130 Free PMC article.

5

Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis.

Svedbom A, Storck C, Kachroo S, Govoni M, Khalifa A. Svedbom A, et al. Patient Prefer Adherence. 2017 Apr 7;11:719-729. doi: 10.2147/PPA.S128665. eCollection 2017. Patient Prefer Adherence. 2017. PMID: 28435230 Free PMC article. Review.

6

Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors.

Dalén J, Svedbom A, Black CM, Kachroo S. Dalén J, et al. Among authors: svedbom a. Rheumatol Int. 2017 Dec;37(12):2049-2058. doi: 10.1007/s00296-017-3825-z. Epub 2017 Oct 3. Rheumatol Int. 2017. PMID: 28975392

7

The value of persistence in treatment with subcutaneous TNF-alpha inhibitors for ankylosing spondylitis.

Svedbom A, Dalén J, Ivergård M, Borse RH, Black CM, Luttropp K, Kachroo S. Svedbom A, et al. Eur J Health Econ. 2020 Feb;21(1):45-54. doi: 10.1007/s10198-019-01110-w. Epub 2019 Sep 14. Eur J Health Econ. 2020. PMID: 31522361

8

Real-world comparative effectiveness of adalimumab, etanercept and methotrexate: a Swedish register analysis.

Svedbom A, Ståhle M. Svedbom A, et al. J Eur Acad Dermatol Venereol. 2020 Mar;34(3):525-532. doi: 10.1111/jdv.15978. Epub 2019 Nov 6. J Eur Acad Dermatol Venereol. 2020. PMID: 31568598

9

Real-World Patient Experience of Switching Biologic Treatment in Inflammatory Arthritis and Ulcerative Colitis - A Systematic Literature Review.

Luttropp K, Dalén J, Svedbom A, Dozier M, Black CM, Puenpatom A. Luttropp K, et al. Among authors: svedbom a. Patient Prefer Adherence. 2020 Feb 17;14:309-320. doi: 10.2147/PPA.S238843. eCollection 2020. Patient Prefer Adherence. 2020. PMID: 32109997 Free PMC article. Review.

10

Dalén J, Luttropp K, Svedbom A, Black CM, Kachroo S. Dalén J, et al. Among authors: svedbom a. Adv Ther. 2020 Sep;37(9):3746-3760. doi: 10.1007/s12325-020-01425-8. Epub 2020 Jul 9. Adv Ther. 2020. PMID: 32647910 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

68 results

Search Page

Filters